Liquidia (NASDAQ:LQDA) Insider Sells $768,550.19 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 20,533 shares of Liquidia stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $768,550.19. Following the completion of the transaction, the insider directly owned 154,514 shares of the company’s stock, valued at approximately $5,783,459.02. This trade represents a 11.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Scott Moomaw also recently made the following trade(s):

• On Monday, December 1st, Scott Moomaw sold 831 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total value of $26,749.89.

Liquidia Trading Up 4.1%

LQDA traded up $1.49 during trading on Tuesday, hitting $38.09. The company’s stock had a trading volume of 2,055,159 shares, compared to its average volume of 2,814,845. Liquidia Corporation has a twelve month low of $11.26 and a twelve month high of $39.29. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The stock’s fifty day moving average price is $31.94 and its 200-day moving average price is $25.40. The firm has a market capitalization of $3.31 billion, a P/E ratio of -26.45, a PEG ratio of 1.19 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The company had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. The company’s revenue for the quarter was up 1106.7% on a year-over-year basis. Analysts anticipate that Liquidia Corporation will post -1.51 EPS for the current year.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined 18.1% to 10,709,682 shares as of Dec. 31 (about 17.6% of shares were sold short) and the days-to-cover was ~11.6. Fewer active shorts can reduce downside pressure and may have contributed to the stock moving higher. (Market data entry)
• Neutral Sentiment: January short-interest data shows 0 shares as of Jan. 12 — this is almost certainly a reporting or data glitch rather than a real liquidation of all short positions. Investors should monitor the next short-interest report for a corrected figure. (Market data entry)
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average $37.43 (≈$2.49M); his stake decreased ~6.03%. This large insider sale may be seen as a negative signal by some investors. SEC Filing
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 (≈$1.38M); his holding fell ~9.52%. SEC Filing
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 (≈$1.02M); his holding fell ~4.50%. SEC Filing
• Negative Sentiment: Other insiders (including Rajeev Saggar, Jason Adair, Scott Moomaw, Sarah Krepp, CAO Dana Boyle) also executed sales on Jan. 12 at ~$37.43 per share, each reducing positions between ~6–11.7%. These combined sales represent significant insider liquidity taken at current prices. Rajeev Saggar SEC Filing Dana Boyle SEC Filing Jason Adair SEC Filing Scott Moomaw SEC Filing Sarah Krepp SEC Filing

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday. BTIG Research reaffirmed a “buy” rating and set a $49.00 price target on shares of Liquidia in a research note on Friday. Jefferies Financial Group boosted their price objective on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday. Needham & Company LLC increased their target price on Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $39.67.

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently modified their holdings of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Liquidia by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after acquiring an additional 1,700 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after purchasing an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after purchasing an additional 16,022 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Liquidia by 6.0% during the 1st quarter. Rhumbline Advisers now owns 85,463 shares of the company’s stock worth $1,261,000 after purchasing an additional 4,811 shares during the period. Finally, Ballentine Partners LLC boosted its holdings in shares of Liquidia by 10.2% in the 2nd quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock worth $151,000 after buying an additional 1,119 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).